Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations
Authors:
- 1 September 2019
- journal article
- editorial
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18 (5) , 579-580
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutationsJournal of Cystic Fibrosis, 2019
- Speeding up access to new drugs for CF: Considerations for clinical trial design and deliveryJournal of Cystic Fibrosis, 2019
- Aligning patients' needs and research priorities towards a comprehensive CF research programJournal of Cystic Fibrosis, 2019
- Beyond the expected: Identifying broad research priorities of researchers and the cystic fibrosis communityJournal of Cystic Fibrosis, 2019
- Intestinal organoids to model cystic fibrosisEuropean Respiratory Journal, 2019
- Rectal Organoids Enable Personalized Treatment of Cystic FibrosisCell Reports, 2019
- CFTR modulator theratyping: Current status, gaps and future directionsJournal of Cystic Fibrosis, 2019
- The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providersThorax, 2017
- Analysis of cystic fibrosis–associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseasesJCI Insight, 2016
- Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosisScience Translational Medicine, 2016